A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 in Japanese Participants
Latest Information Update: 18 May 2023
At a glance
- Drugs ARO PNPLA3 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 12 May 2023 Status changed from recruiting to discontinued due to business judgement.
- 31 Jan 2023 Planned primary completion date changed from 28 Nov 2022 to 16 Feb 2023.
- 19 Jul 2022 Planned number of patients changed from 27 to 18.